Clicky

Lisata Therapeutics, Inc.(LSTA)

Description: Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).


Keywords: Biotechnology Biopharmaceutical Life Sciences Emerging Technologies Disease Stem Cell Cell Therapy Regenerative Medicine Chronic Kidney Disease Stem Cell Therapy Angina Cell Therapy Products Japan Treatment For Chronic Kidney Disease

Home Page: www.lisata.com

LSTA Technical Analysis

110 Allen Road
Basking Ridge, NJ 07920
United States
Phone: 908 842 0100


Officers

Name Title
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. CEO & Director
Dr. Kristen K. Buck M.D. Exec. VP of R&D and Chief Medical Officer
Mr. David Slack MBA Pres, Chief Bus. Officer & Director
Mr. James Nisco VP of Fin. & Treasury
Mr. Gregory S. Berkin Chief Information Officer
Mr. John D. Menditto VP of Investor Relations & Corp. Communications
Eric Powers Director of Communications and Marketing
Ms. Gail Holler VP of HR
Dr. Ian Zhang MBA, Ph.D. Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc
Dr. William K. Sietsema Ph.D. VP of Global Regulatory Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.3165
Price-to-Sales TTM: 0
IPO Date: 1999-03-01
Fiscal Year End: December
Full Time Employees: 27
Back to stocks